Clinical Trials Logo

Filter by:
NCT ID: NCT03671551 Terminated - Clinical trials for Psychomotor Development Impaired

Study of Psychomotor Development and Attachment in Children Aged 6 to 30 Months With Oral Disorder

TODEVA
Start date: November 19, 2018
Phase:
Study type: Observational

Dietary difficulties and eating disorders of the child are a common reason for consulting infants and young children. There is currently little data on the psychomotor development of these children and their association with parent-child attachment. The objective of this study is to evaluate, at the same time, the three physiological, psychomotor and attachment dimensions of children with eating disorders.

NCT ID: NCT03669549 Terminated - Clinical trials for Congenital Adrenal Hyperplasia

Nevanimibe HCl for the Treatment of Classic CAH

Start date: July 11, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, intra-subject dose-titration open-label study of nevanimibe hydrochloride (HCl) for the treatment of classic congenital adrenal hyperplasia (CAH). Following a Screening Period of approximately 2-14 weeks, eligible subjects will enter a Baseline Period of approximately 2-8 weeks and then a 16-week Treatment Period. It is anticipated that the overall duration of the study per subject will range from 24-42 weeks.

NCT ID: NCT03667365 Terminated - Clinical trials for Aortic Valve Stenosis

Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction

ROTAS
Start date: March 19, 2019
Phase: N/A
Study type: Interventional

According to current European Recommendations on valvular heart disease (VHD), "classical" severe aortic stenosis (AS) is defined by an aortic valve area (AVA) ≤1 cm2 and indexed AVA ≤0.6 cm2/m2, a mean aortic pressure gradient (MAG) >40 mmHg, and a maximal aortic velocity >4 m/sec. Aortic valve replacement (AVR) is recommended (class I indication) in patients with "classical" severe AS who have any symptoms related to aortic valve disease. In 2007, Hachicha et al. described a particular pattern of severe AS, characterized by an AVA ≤0.6 cm2/m2, low mean pressure aortic gradient (MAG <40 mmHg), despite the presence of a preserved left ventricular ejection fraction (LVEF ≥50%). This pattern of AS is encountered in nearly 15-25 % of patients who have severe AS. Typically, these patients are elderly subjects, with several comorbidities, a small left ventricular (LV) cavity with pronounced LV concentric remodeling and a restrictive physiology, leading to a decrease in LV stroke volume despite a preserved LVEF. The diagnosis and management of patients with low gradient severe AS and preserved LVEF are often challenging because: 1. the presence of a "true" severe aortic stenosis should be carefully confirmed by a multi-modality imaging approach; 2. the best therapeutic management (AVR versus conservative strategy) of symptomatic patients with low gradient severe AS and preserved LVEF is not clearly established. In very recently updated European guidelines on the management of VHD, symptomatic patients with low gradient and low flow severe AS and preserved LVEF have only a class IIa-level C indication for AVR. No specific indications are given for the management of symptomatic patients with low gradient and normal flow severe AS. This lack of indications is clearly attributed to a gap in knowledge which requires further investigations to be filled up.

NCT ID: NCT03667339 Terminated - Clinical trials for Direct Anterior Total Hip Arthroplasty

Direct Anterior Total Hip Arthroplasty (THA), in Versus Outpatients : A Prospective Monocentric Study in Rennes University Hospital.

AHVACA
Start date: March 27, 2018
Phase:
Study type: Observational

The main objective is to show that cumulative length of stay over the first 45 post operative days (i.e. : primary length of stay and readmission) is significantly lower in the outpatients group than in the inpatients group

NCT ID: NCT03665129 Terminated - Clinical trials for Advanced Solid Tumors

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

STELLAR-001
Start date: September 7, 2018
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.

NCT ID: NCT03656640 Terminated - Autoimmune Diseases Clinical Trials

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

Start date: November 23, 2016
Phase:
Study type: Observational

This observational trial assesses the safety and efficacy of Gammanorm® in autoimmune diseases.

NCT ID: NCT03656510 Terminated - Clinical trials for Respiratory Syncytial Virus Infections

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

Start date: November 29, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetic/pharmacodynamic relationships of different oral dose levels of JNJ-53718678 in children greater than or equal to 28 days and less than or equal to 3 years of age with respiratory syncytial virus (RSV) disease (hospitalized participants [Cohort 1] or outpatients [Cohort 2]).

NCT ID: NCT03654989 Terminated - Diabetic Foot Ulcer Clinical Trials

Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers

InTREPiD
Start date: January 28, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Assess the effect of iontophoresis of treprostinil on wound closure over 12 weeks, in patients with DFU. In the present study the investigators aim at establishing the proof-of-concept of iontophoresis of treprostinil as a potential treatment of diabetic foot ulcers in humans. The main hypothesis is that in patients with DFUs, the pharmacodynamic effect of a PGI2 analogue potentiates the effect of low-intensity current on microvascular function, tissue oxygenation and healing.

NCT ID: NCT03654729 Terminated - Colorectal Cancer Clinical Trials

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

POLAR-M
Start date: November 7, 2018
Phase: Phase 3
Study type: Interventional

This study evaluates the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by the drug oxaliplatin.

NCT ID: NCT03653533 Terminated - Type I Diabetes Clinical Trials

Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump

AAHPI
Start date: January 7, 2019
Phase: N/A
Study type: Interventional

This study compares the apparition of hypoglycaemia in type I diabetic patients between 2 phases: the one without the use of SmartGuard® function and the one with the use of SmartGuard® function.